- Home
- PHAR vs EYPT Comparison
PHAR vs EYPT Comparison
Compare PHAR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- EYPT
- Stock Information
- Founded
- PHAR 1988
- EYPT 1987
- Country
- PHAR Netherlands
- EYPT United States
- Employees
- PHAR N/A
- EYPT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PHAR Health Care
- EYPT Industrials
- Exchange
- PHAR Nasdaq
- EYPT Nasdaq
- Market Cap
- PHAR 679.0M
- EYPT 594.5M
- IPO Year
- PHAR N/A
- EYPT 2005
- Fundamental
- Price
- PHAR $9.55
- EYPT $7.63
- Analyst Decision
- PHAR Strong Buy
- EYPT Strong Buy
- Analyst Count
- PHAR 3
- EYPT 8
- Target Price
- PHAR $27.00
- EYPT $25.71
- AVG Volume (30 Days)
- PHAR 5.4K
- EYPT 890.7K
- Earning Date
- PHAR 03-13-2025
- EYPT 03-06-2025
- Dividend Yield
- PHAR N/A
- EYPT N/A
- EPS Growth
- PHAR N/A
- EYPT N/A
- EPS
- PHAR N/A
- EYPT N/A
- Revenue
- PHAR $285,745,000.00
- EYPT $45,713,000.00
- Revenue This Year
- PHAR $20.08
- EYPT N/A
- Revenue Next Year
- PHAR $9.22
- EYPT N/A
- P/E Ratio
- PHAR N/A
- EYPT N/A
- Revenue Growth
- PHAR 30.64
- EYPT 7.50
- 52 Week Low
- PHAR $6.65
- EYPT $6.90
- 52 Week High
- PHAR $13.20
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- PHAR 50.97
- EYPT 46.11
- Support Level
- PHAR $9.37
- EYPT $7.15
- Resistance Level
- PHAR $10.01
- EYPT $8.25
- Average True Range (ATR)
- PHAR 0.52
- EYPT 0.64
- MACD
- PHAR -0.10
- EYPT -0.01
- Stochastic Oscillator
- PHAR 28.08
- EYPT 27.80
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.